Mar 16, 2023 7:00 am EDT NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test
Mar 13, 2023 7:00 am EDT NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
Feb 28, 2023 7:00 am EST NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference
Feb 6, 2023 7:00 am EST NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
Feb 6, 2023 7:00 am EST RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
Nov 21, 2022 7:00 am EST RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
Nov 18, 2022 9:20 am EST NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
